December 20, 2024

Bio-interventional Cyclodialysis with Allograft Scleral Reinforcement for OAG

The combined procedure decreased IOP and improved BCVA.

Conexiant

December 20, 2024

Empagliflozin Reduces Risk of Diabetic Retinopathy Progression

Investigators found a 22% reduced risk of progression in patients with preexisting NPDR.

Conexiant

December 20, 2024

Workplace Discrimination in Ophthalmology

“Your husband also works, so you’re the second income.’”

Conexiant

December 20, 2024

Introducing the Quirky Clinic

Each week we’ll dive into the strangest and most surprising medical stories, from cutting-edge science to unbelievable true tales.

Conexiant

December 17, 2024

New TED Drug Positioned for Success

A groundbreaking late-stage study highlights the effectiveness of Viridian Therapeutics' novel treatment, veligrotug, for chronic thyroid eye disease, offering hope for more convenient and efficient therapy. Positive results led to a substantial boost in the company's stock price.

Reuters

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 13, 2024

Obstructive Sleep Apnea Affects nAMD

The potential overnight reduction of the critical oxygen supply could present a retinal health risk.

Conexiant

December 13, 2024

Faricimab Shows Better Anatomic Outcomes Compared to Aflibercept for nAMD

New data from TENAYA and LUCERNE supports “the vascular stabilizing effects of Ang-2 inhibition beyond anti-VEGF-A alone.”

Conexiant